8-K current report · filed Sep 3, 2026

Liquidia Corp (LQDA) 8-K Current Report: September 3, 2026

Item EX-99.1Item 8.01LQDA overview

Short answer

Liquidia Corp (LQDA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). FDA Fast Track Designation granted to YUTREPIA for Raynaud’s phenomenon associated with systemic sclerosis.

Liquidia Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA Fast Track Designation granted to YUTREPIA for Raynaud’s phenomenon associated with systemic sclerosis
  • Regulatory milestone may accelerate FDA interactions and development of this potential new indication
  • Expands YUTREPIA’s addressable market beyond pulmonary hypertension applications

Item EX-99.1 · Exhibit EX-99.1

  • FDA Fast Track designation for YUTREPIA in SSc-RP, potentially enabling closer FDA interaction and rolling NDA review
  • Addressable U.S. population estimated at approximately 30,000 moderate-to-severe SSc-RP patients
  • RE-WARM Phase 2a study planned for October 2026, enrolling approximately 75 adults across up to 30 sites
  • Primary completion targeted for February 2027, creating a near-term clinical catalyst
  • SSc-RP indication remains unapproved and unvalidated; Fast Track does not ensure efficacy or eventual FDA approval

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Liquidia Corp 8-K filings

Get the next LQDA 8-K as it lands

Follow LQDA for push alerts, or ask the research agent what this filing means.